, Tracking Stock Market Picks
Enter Symbol:
Colgate-palmolive Company (CL) [hlAlert]

Buy CL
up 66.24 %

Colgate-palmolive Company (CL) rated Buy

Posted on: Wednesday,  Oct 31, 2007  3:25 PM ET by Oppenheimer

Oppenheimer rated Buy Colgate-palmolive Company (NYSE: CL) on 10/31/2007, when the stock price was $37.95. Since
then, Colgate-palmolive Company has gained 66.25% as of 09/02/2015's recent price of $63.09.
If you would have followed this Oppenheimer's recommendation on CL, you would have gained 66.24% of your investment in 2863 days.

Colgate-Palmolive is a leading global consumer products company, tightly focused on Oral Care, Personal Care, Household Surface Care, Fabric Care and Pet Nutrition. Colgate sells its products in countries and territories around the world under such internationally recognized brand names as Colgate, Palmolive, Mennen, Softsoap, Irish Spring, Protex, Sorriso, Kolynos, Ajax, Axion, Soupline, Suavitel and Fab, as well as Hill's Science Diet and Hill's Prescription Diet pet foods. (Company Press Release)

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/31/2007 3:25 PM Buy
37.95 43.00
as of 8/27/2015
1 Week down  -4.39 %
1 Month down  -5.84 %
3 Months down  -8.07 %
1 YTD down  -3.25 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy